Market Runner: Will Moleculin Biotech Inc Short Squeeze Soon?

Market Runner: Will Moleculin Biotech Inc Short Squeeze Soon?

The stock of Moleculin Biotech Inc (NASDAQ:MBRX) is a huge mover today! About 89,763 shares traded hands. Moleculin Biotech Inc (NASDAQ:MBRX) has risen 6.00% since October 19, 2016 and is uptrending. It has outperformed by 1.57% the S&P500.
The move comes after 7 months negative chart setup for the $37.31M company. It was reported on Nov, 18 by Barchart.com. We have $2.50 PT which if reached, will make NASDAQ:MBRX worth $4.85 million less.

Analysts await Moleculin Biotech Inc (NASDAQ:MBRX) to report earnings on November, 21.

According to Zacks Investment Research, “Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX.”

More notable recent Moleculin Biotech Inc (NASDAQ:MBRX) news were published by: Streetinsider.com which released: “Moleculin Biotech (MBRX) Receives Positive FDA Guidance Regarding Annamycin …” on November 17, 2016, also Quotes.Wsj.com with their article: “News Moleculin Biotech Inc.MBRX” published on February 11, 2011, Marketwired.com published: “Moleculin Biotech, Inc. Completes Initial Public Offering; MBRX Shares Set to …” on June 01, 2016. More interesting news about Moleculin Biotech Inc (NASDAQ:MBRX) were released by: Marketwired.com and their article: “Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended …” published on August 15, 2016 as well as Marketwatch.com‘s news article titled: “Virtual Stock Exchange” with publication date: June 02, 2016.

MBRX Company Profile

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Firm is focused on the development of anti-cancer drug candidates, many of which are based on license agreements. The Company’s lead drug candidate is liposomal Annamycin (Annamycin). The Firm has two other drug development projects in progress, one involving a portfolio of small molecules, known as the WP1066 Portfolio, and the other is WP1122 Portfolio. WP1066 Portfolio is focused on the modulation of key regulatory transcription factors involved in the progression of cancer. WP1122 Portfolio is a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma (a form of brain tumor).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment